{{Rsnum
|rsid = 28940870
|Gene = SERPING1
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=A
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Chromosome=11
|position=57614474
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|Gene_s=SERPING1
}}[[rs28940870]] represents a dominant (though rare) mutation in the [[SERPING1]] gene, resulting in type II hereditary [[angioedema]]. {{PMID|3178731|OA=1
}}

In October 2008, the US Food and Drug Administration (FDA) approved a C1 inhibitor human protein [[Cinryze]] to help prevent attacks in patients with hereditary angioedema.[http://www.fda.gov/CBER/products/Cinryze.htm] In clinical trials, [[Cinryze]] was effective in preventing or decreasing the frequency of attacks in most but not all patients with hereditary angioedema, which may be caused by several different mutations, one of which is [[rs28940870]].

{{omim
|desc=ANGIOEDEMA, HEREDITARY, TYPE II
|id=606860
|rsnum=28940870
|variant=0005
}}

{{omim
|id=606860
|rsnum=28940870
|variant=0004
}}

{{ClinVar
|rsid=28940870
|Reversed=0
|FwdREF=C
|FwdALT=A,T
|REF=C
|ALT=A,T
|RSPOS=57381947
|CHROM=11
|dbSNPBuildID=132
|SSR=0
|SAO=1
|VP=0x050368000000000002110100
|GENEINFO=SERPING1:710
|GENE_NAME=SERPING1
|GENE_ID=710
|WGT=0
|VC=SNV
|CLNALLE=1; 2
|CLNHGVS=NC_000011.9:g.57381947C>A; NC_000011.9:g.57381947C>T
|CLNSRC=OMIM Allelic Variant; UniProtKB (variants)
|CLNORIGIN=1
|CLNSRCID=606860.0005; VAR_007022; 606860.0004; VAR_007019
|CLNSIG=5
|CLNCUI=C1862892
|CLNDBN=Hereditary angioedema, type II; not provided
|Disease=Hereditary angioedema; not provided
|CLNACC=RCV000004154.1; RCV000059083.1; RCV000004153.1; RCV000059084.1
|Tags=PM;PMC;S3D;SLO;OTHERKG;LSD;OM
|CLNDSDB=MedGen
|CLNDSDBID=C1862892
}}

{{PMID Auto
|PMID=22994404
|Title=Mutational spectrum and geno-phenotype correlation in Chinese families with hereditary angioedema.
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}